Immune boosting duo takes on rare throat cancer
NCT ID NCT03097939
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase II trial tests whether combining two immunotherapy drugs, ipilimumab and nivolumab, can shrink tumors in people with advanced nasopharyngeal carcinoma (NPC) linked to the Epstein-Barr virus. About 113 patients with recurrent or metastatic NPC that can't be cured will receive the drugs every few weeks. The main goal is to see how many patients have their tumors shrink or disappear.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Ipilimumab (Yervoy) and Nivolumab (Opdivo)
- What this could lead to
- If successful, this combination could offer a new treatment option for advanced nasopharyngeal carcinoma, potentially shrinking tumors and delaying disease progression.
- What could go wrong
- This is a mid-stage trial with 113 participants, so results may not apply to everyone. The drugs can cause immune-related side effects, and not all patients may respond.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NASOPHARYNGEAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Cancer Center Singapore
Singapore, 169610, Singapore
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could adding extra chemo before standard therapy beat nasopharyngeal cancer?
- Smart T-Cell engager aims to outsmart tumors in first human test
- Immunotherapy combo shows promise in shrinking Hard-to-Treat head and neck tumors
- Immunotherapy duo aims to shrink nasopharyngeal tumors before standard treatment
- New radiation approach aims to reduce dry mouth in throat cancer patients
- New pill-chemo combo takes on hard-to-treat cancers